๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of m-AMSA in patients with malignant mesothelioma

โœ Scribed by Geoffrey Falkson; Daniel A. Vorobiof; Harvey J. Lerner

Publisher
Springer
Year
1983
Tongue
English
Weight
330 KB
Volume
11
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II study of gemcitabine in patie
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
โœ Jan P. van Meerbeeck; Paul Baas; Channa Debruyne; Harry J. Groen; Chris Manegold ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 115 KB ๐Ÿ‘ 2 views

## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo

Gemcitabine combined with carboplatin in
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma : A multicentric Phase II study
โœ Adolfo G. Favaretto; Savina M. L. Aversa; Adriano Paccagnella; Vincenzo De Pangh ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide. Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated.

A phase II study of VP-16 and cisplatin
A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma
โœ Elizabeth A. Eisenhauer; William K. Evans; Nevin Murray; Walter Kocha; Rafal Wie ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 204 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group has carried out a phase II study of VP-16 100 mg/m 2 daily x 3 and cisplatin 25 mg/m 2 daily x 3 in untreated patients with malignant mesothelioma. Twenty-seven eligible patients were entered on the trial and the majority had pleur